← All trials
NCT00147004
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2002
- Primary completion
- Nov 1, 2005
- Completion date
- Nov 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Hebrew UniversityLead sponsor
- University of GenevaStudy director
- University of LondonStudy director
- Hospital de St. António dos CapuchosStudy director
- European Society of Intensive Care MedicineCollaborator
- International Sepsis ForumCollaborator
- The Gorham FoundationCollaborator
- Hôpital Raymond PoincaréStudy director
- Ludwig Maximilians UniversityStudy director
- Humboldt UniversityStudy director
- Hebrew UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.